Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM + Thymoglobulin and HCT for Autoimmune Neurologic Diseases
NCT00716066Phase 2Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2008
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of carmustine, etoposide, cytarabine, melphalan, antithymocyte globulin rabbit, sponsored by Fred Hutchinson Cancer Center. Started Jun 2008; status: active, not recruiting.
02
Drugs
carmustineetoposidecytarabinemelphalanantithymocyte globulin rabbit
Beyond the preview
Go deeper on NCT00716066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00716066.